报价延迟最少15分钟:2026/03/30 20:36 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
17.85 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-1.60/-0.24
|
|
企业价值
2.03B
|
| 资产负债 |
|
每股账面净值
6.35
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
460.16M
|
|
每股收益
2.35
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others. |
